Indian Psoriasis Drugs Market size stood at USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period (2019-2028).

The Psoriasis use to trigger by certain environmental and genetic factors. Changing lifestyles of people are leading to increased alcohol consumption and smoking, an unhealthy diet, and sedentary living, which makes people more prone to this condition. Up to XX% of patients suffer from depression due to psoriasis in India. Psoriasis is an autoimmune caused due to an abnormal multiplication of skin cells. The incidence of psoriasis ranges between 0.09% and 11.4% in India. It is also found that it commonly occurs in the age group of 50 to 69. Indias first home-grown brand will provide a new therapy and increase drug sales for Psoriasis. India is also contributing to the market growth as their populations obtain increasing access to PsO pharmacotherapy. Growing awareness amongst the individuals will further boost various opportunities that will lead to the growth of the psoriasis treatment market.



Market Drivers

The major factors influencing the growth are increasing prevalence of psoriasis, availability of better, advanced diagnostic devices results in constructing assurance in people, rising healthcare expenditure increasing research and development for the treatment of psoriasis, better medical facilities, commercialization of new diagnostic technology, medical policies, and favorable reimbursement policies, increasing awareness for the treatment, and development of advanced technology. Increasing demand of psoriasis medicines in emerging economies, development of long-lasting drugs is also contributing to the growth of the market.